The number of metastatic sites for stage IIIA endometrial carcinoma, endometrioid cell type, is a strong negative prognostic factor

Gynecologic Oncology

Volumn 117, Issue 1, 2010, Pages 32-36

  Jobsen, Jan J ^a   ten Cate, Lambert Naudin ^b   Lybeert, Marnix L M ^c   van der Steen Banasik, Elzbieta M ^d   Scholten, Astrid ^e   van der Palen, Job ^a,f   Slot, Annerie ^g   Kroese, Marika C Stenfert ^h   Schutter, Eltjo M J ^a   Siesling, Sabine ⁱ  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b Laboratorium Pathologie Oost Nederland   (Netherlands)

^c CATHARINA HOSPITAL   (Netherlands)

^d Arnhems Radiotherapeutisch Instituut   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF TWENTE   (Netherlands)

^g Radiotherapy Institute Friesland   (Netherlands)

^h Radiotherapy Institute Stedendriehoek en Omstreken   (Netherlands)

ⁱ Integraal Kankercentrum Noord Nederland   (Netherlands)

Author keywords

Endometrial carcinoma; Heterogeneity; Outcome; Stage IIIA

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RECURRENCE RISK;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING;

EID: 77949334482     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.12.010     Document Type: Article

References (21)

1. Jemal A., Thomas A., Murray T., et al. Cancer statistics. CA Cancer J. Clin. 52 (2002) 23-47
2. www.cancerregistry.nl.
3. th edition 1997.
4. Creasman W.T., Odicino F., Maisonneuve P., et al. International Federation of Gynecology and Obstetrics, annual report on the results of treatment in gynecologic cancer. J. Epidemiol. Biostat. 6 (2001) 45-86
5. Kasamatsu T., Onda T., Katsamatu N., et al. Prognositc significance of peritoneal cytology in endometrial carcinoma confined to the uterus. Br. J. Cancer 27 (2003) 245-250
6. Bruckman J.E., Bloomer W.D., Marck A., et al. Stage III adenocarcinoma of the endometrium: two prognostic groups. Gynecol. Oncol. 9 (1980) 12-17
7. Grigsby E.W., Perez C.S., Kuske R.R., et al. Results of therapy analysis of failures and prognostic factors for clinical and pathologic stage III adenocarcinoma of the endometrium. Gynecol. Oncol. 27 (1987) 44-57
8. Connell P.P., Rotmensch J., Waggoner S., et al. The significance of adnexal involvement in endometrial carcinoma. Gynecol. Oncol. 74 (1999) 74-79
9. Eltabbakh G.H., Piver M.S., and Hempling R.E. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial. Int. J. Radiat. Oncol. Biol. Phys. 38 (1997) 373-380
10. Mariani A., Webb M.J., and Keeney G.L. Assessment of prognostic factors in stage IIIA endometrial cancer. Gynecol. Oncol. 86 (2002) 38-44
11. Greven K.M., Lanciano R.M., Corn B., et al. Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence. Cancer 71 (1993) 3697-3702
12. Tebeu P.M., Popowski Y., Verkooijen H.M., et al. Positive peritoneal cytology in early-stage endmetrial cancer does not influence prognosis. Br. J. Cancer 19 (2004) 720-724
13. Kadar N., Homesley H.D., and Malfetano J.H. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol. Oncol. 46 (1992) 145-149
14. Slomovitz B.M., Ramondetta L.M., and Lee C.M. Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy. Int. J. Gynecol. Cancer 15 (2005) 510-516
15. Creutzberg C.L., van Putten W.L.J., Koper P.C.M., et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-I endometrial carcinoma: multicentre randomised trial PORTEC STUDY GROUP. Post operative radiation therapy in endometrial carcinoma. The Lancet 355 (2000) 1404-1411
16. Jobsen J.J., Lybeert M.L.M., Steen-Banasik E.M., et al. Multi-centre cohort study on treatment results and risk factors in stage II endometrial carcinoma. Int. J. Gynecol. Cancer. 18 (2008) 1071-1078
17. Ashman J.B., Connell P.P., Yamada D., et al. Outcome of endometrial carcinoma patients with involvement of the uterine serosa. Gynecol. Oncol. 82 (2001) 338-343
18. Morrow C.P., Bundy B.N., Kurman R.J., et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol. Oncol. 40 (1991) 55-65
19. Anderson P.R. The role of radiation therapy in locally advanced endometrial cancer. Sem. Radiat. Oncol. 16 (2006) 152-157
20. Schorge J.O., Molpus K.L., Goodman A., et al. The effect of postsurgical therapy on stage III endometrial carcinoma. Gynecol. Oncol. 63 (1996) 34-39
21. Preyer O., Obermair A., and Formann E. The impact of positive washings and serosal and adnexal involvement on survival in patients with stage IIIA uterine cancer. Gynecol. Oncol. 86 (2002) 269-273